Retatrutide (you may see it called the "triple agonist" or informally "GLP-3") is an experimental weight-management drug being developed by a major pharmaceutical company. It's designed to activate three hormone pathways at once — GLP-1, GIP, and glucagon — where current approved drugs work on one or two. Early trial results have drawn a lot of attention, but it is still being studied.
| What You'll See Online | The Honest Version |
|---|---|
| "The most powerful one ever" | Early trial data is striking — but trials are still ongoing and full safety and long-term data aren't in yet. |
| "Buy reta now from [vendor]" | Red flag. It's not approved or available by prescription. Anything for sale is unverified and unsafe. |
| "Doctors are prescribing it" | They can't — it's investigational. Only clinical-trial participants receive the studied drug. |
| "Same as Mounjaro/Wegovy" | No. Those are FDA-approved. Retatrutide is a different, still-experimental molecule. |